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p7 of HCVViral channel forming proteins are known for their capability to make the lipid membrane of the host cell and its
subcellular compartments permeable to ions and small compounds. There is increasing evidence that someof the
representatives of this class of proteins are also strongly interacting with host proteins and the effectiveness of
this interaction seems to be high. Interaction of viral channel proteinswith host factors has beenproposed bybio-
informatics approaches and has also been identiﬁed experimentally. An overview of the interactions with host
proteins is given for Vpu from HIV-1, E5 from HPV-16 and p7 from HCV. This article is part of a Special Issue
entitled: Viral Membrane Proteins — Channels for Cellular Networking.
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ights reserved.1. Introduction
Viruses hijack the cell just using their proteins and DNA/RNA. By
steering the cell viruses improve their own replication. The improve-
ment could be an alteration of ion and substrate concentrations in
cellular sub-compartments, the generation of additional cellular sub-
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stimulation of cell growth factors. The virus does not produce viral hor-
mones to conduct these tasks. The only knownmechanism of retroviral
proteins is through viral-host protein–protein interactions.
Viral globular andmembrane proteins are used for reproduction and
steering of host factors. For the latter, interaction is not only between
extramembrane parts of viral and host proteins but also between the
transmembrane domains. Themembrane allows electrochemical gradi-
ents to be generated.Withmembrane proteins the stored energy can be
harvested to drive viral replication. A large number of viruses are iden-
tiﬁed to harbor short membrane proteins with one to three transmem-
brane spanning domains able to exploit electrochemical or substrate
gradients in the host cell. A major characteristic of these proteins is
that they form oligomers similar to their cellular ion channel compan-
ions but are very much smaller in size. It is these two issues, cellular
steering of host proteins and channel formation, within the lipid mem-
branewhichmake these proteins a highly attractive topic to investigate.
In addition some of these proteins have emerged already as highly im-
portant drug targets.
Investigations of viral membrane proteins have seen the emergence
of research focusing on ‘viral channel forming proteins’ [1,2], also
named as ‘viroporins’ [3,4], which are identiﬁed to render lipid mem-
branes permeable to ions and substrates [5]. One of these proteins, M2
from inﬂuenza A, has been a major antiviral drug target. Stimulated by
the importance of this protein, a successful search for viral channel pro-
teins has been intensiﬁed and lead to an increasing number of potential
candidates [2,6]. Viral channels are formed by either bitopic, or
polytopic membrane proteins with 2 and 3 TMDs (Fig. 1). For most of
these viral channel proteins their role within the infectivity cycle is yet
to be identiﬁed.
Within the family of viral channel proteins, Vpu from HIV-1 is one of
the most controversial channel proteins. Despite the identiﬁcation of
this protein to form channels in artiﬁcial bilayers [7] and to increase con-
ductivity in infectedXenopus oocytes [7,8], its role as a channel has not yet
been identiﬁed (see K. Strebel, this issue). At the same time of its identiﬁ-
cation to form ion channels, its role to down-regulate receptor proteins
has been found [9,10] (Fig. 1).Within recent years the number of host fac-
tors beenmanipulated byVpuhas risen.With the classiﬁcation of E5 from
HPV to be a viral channel protein in 2012 [11], there seems to be a most
recent ‘novel’ member of the channel family. Before that time in 2012,
E5 has actually been known for a long time for its role as a host factorma-
nipulator interacting with host proteins.
Thus the question arises, are the virus-encoded channel proteins a
single task-unit or can they adopt multiple roles? It is still not clear
whether structurally distinct features such as orientation or state of
oligomerization of the proteins are necessary to fulﬁll the tasks or
whether there is equilibrium between the different features (Fig. 2).
In this review the focus is on Vpu of HIV-1, E5 of HPV and p7 of HCV
for which the interactions with host factors have been experimentally
identiﬁed or have been proposed by bioinformatics approaches.
2. Vpu of human immunodeﬁciency virus type 1
Vpu is a bitopic 81 amino acid type Imembrane protein expressed in
the late life cycle of human immunodeﬁciency virus type 1 [12,13]. Its
role in the infectivity cycle is to enhance particle release via interaction
with host factors and also via channel functionality (see recent reviews
[2,4]). Its short N terminal extramembrane part of a few amino acids
leads into a transmembrane domain (TMD) which is highly hydropho-
bic, consisting of a single leucine and multiple isoleucines and valines.
It harbors a single hydrophilic residue, Ser-24, proceeded by Trp-23.
The sequence then enters into the cytoplasmic domain via an EYR-
motif which probably functions as a hinge between the two domains.
Serines at positions 52 and 56 are identiﬁed to be phosphorylated [10].
The capability to form channels has been discovered using electro-
physiological measurements on artiﬁcial lipid bilayers [7]. Independentlychannel activity has been conﬁrmed also by other groups using the same
techniques [14]. The protein has been identiﬁed to generate a weakly se-
lective pore [7,14–16].Mutationswithin the TMDof the protein are alter-
ing channel kinetics [7,16]. In particular, mutating Ser-24 leads to an
abrogation of channel activity of a respective peptide corresponding to
the TMD of Vpu [16]. Evidence of Vpu mediated leakage of small mole-
cules from Escherichia coli has also been reported [17]. Physiologicalmea-
surements on Vpu expressed in Xenopus oocytes and 293T cells support
the ability of the protein to form channels [7,18].
Summarizing the evidences, up to now all channel characteristics
are based on peptides and full length proteins reconstituted into artiﬁ-
cial lipidmembranes orwhenover expressing a Vpu containing plasmid
in cells.
Identiﬁcation of channel formation of Vpu has had implications
on the computational modeling of the protein. The ﬁrst computa-
tional model of the membrane embedded part of Vpu is a pentameric
assembly of the helical TMDs [19] (Fig. 1A). The helical motif has
been chosen in analogy to the M2 channel from inﬂuenza A. With
the bundle model ion selectivity has been proposed on a structural
level by calculating potential energy proﬁles of Na and Cl ions
along the bundle axis. These data have later been conﬁrmed when
calculating the potential of mean force for monovalent ions being
pulled through a pentameric TMD bundle [20]. In another study
combining bilayer recordings with computational modeling a tetra-
meric bundle, based on modeling the TMD, has been discarded
[21]. Molecular dynamics simulations have also revealed that
hexameric bundles of the TMDs do not remain in a pore like structure
when simulated for several nanoseconds [22]. Also other assemblies,
pentameric and tetrameric bundles, do not remain in a bundle struc-
ture when simulated for longer time scales [23].
2.1. Interaction with CD4
Almost parallel to the emerging evidences that Vpu forms a channel
it has been discovered that Vpu down-regulates the receptor protein
CD4 (Fig. 1A) from the infected cell [9,24–26] reviewed in [25]
(Table 1). For the down-regulation, the two phosphorylation sites,
Ser-52 and Ser-56, have been found to be essential aswell as an interac-
tion with the cytoplasmic domain of CD4 [27]. Without the phospho-
rous groups, Vpu is still able to contact CD4, but down-regulation is
hampered [10,24,28]. Mutation studies on both CD4 and Vpu have iden-
tiﬁed structural and sequence speciﬁc motifs on both proteins which
seem to be essential for interaction. It has been reported that a stretch
in CD4, Arg-396 to Lys-417, is predicted to be helical and essential for
phosphorylation-dependent down-regulation of CD4 [29]. Solution
NMR spectroscopic data of a CD4mutant construct recorded inmicelles
conﬁrm a helical motif of the membrane-proximal cytoplasmic stretch
Ala-404 to Leu-413 of CD4 [30]. A deletion mutant of CD4 in this region
identiﬁes the stretch, KRLLSEKKT, in this cytoplasmic domain to be
essential for the Vpu binding [31]. Substitution mutations in this region
have not resulted in abrogation of Vpu binding. Therefore, it has been
suggested that the mutations may have not led to a derangement of
the helical motif and that this motif is important for proper interaction
with Vpu. As far as Vpu is concerned it is reported that both cytoplasmic
helices are involved in CD4down-regulation [31]. Especiallywhen short
speciﬁc amino acid sequences within the ﬁrst cytoplasmic helix of Vpu
are mutated, e.g. the short stretches YRK or DRLI, as well as the single
mutation L63P, Vpu loses its capability to down-regulate CD4. Since all
the mutations are generated to disrupt the helical motif it is concluded
that for Vpu-mediated CD4 down-regulation a helix–helix interaction
motif is essential.
The structure of the cytoplasmic domain of Vpu as a whole and also
individual parts of this domain have been decipheredby various authors
using different techniques such as solution [32–35] and solid state NMR
spectroscopy [36,37], as well as CD spectroscopy [32,35]. The current
structural model of Vpu is comprised of a helical TMD, linked to the
Fig. 1. (A) Computationalmodels of theﬁrst 32 amino acids including the transmembrane domain (TMD) of the bitopic Vpu (Vpu1–32) fromHIV-1 (VpuHV1H2) [23]. The TMD of Vpu1–32
is modeled in its interacting form with the TMD of the receptor protein CD4 (blue, left), BST-2 (green, middle) and NTB-A (yellow, right) in the upper panel. The lower panel shows
potential pentameric assemblies of Vpu1–32 as a hydrophobic pore (left) and a pore with hydrophilic residue serine (yellow) facing the inside of the bundle (right). The putative mono-
meric form of E5 protein seen from the side of TMD2 (B). Serine residues (yellow) and threonines (blue) are shown in van der Waals spheres. A putative hexameric bundle with TMD2s
facing the pore is also shown (right). (C) The polytopic channel protein p7 from HCV is shown as a monomer with its two TMDs aligned antiparallel (left) and in a putative hexameric
bundle (right). The models highlight the histidine residues (red), which are thought to face the lumen of the pore. All models are generated with surface mode of MOE software suite
coloring hydrophilic residues in green and hydrophilic residues in blue. The backbones of the TMDs are shown in light yellow.
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Table 1
Host proteins interacting with the viral proteins Vpu of HIV-1, E5 of HPV-16 and p7 of HCV. Host proteins are identiﬁed by experiments or bioinformatics tools [96]. HPRD ID: human
protein reference database identiﬁcation number; SVM: support vector machine; ELM: eukaryotic linear motif (http://elm.eu.org/).
Host protein
(HPRD IDs, ELM)








CD4 1 Cytoplasmic region Immunoprecipitation [121,27]
TASK 4 TMD Sequence similarity, coimmunoprecipitation [38]
BST-2 1 TMD NMR, co-immunoprecipitation,
western blot analysis, ﬂow cytometry
[41,42,44,45,50]
NTB-A 1 TMD Immunoprecipitation, western blot analysis [53]




Found in type I transmembrane
proteins
Comparison of ELMs [58]
E5





COX-2, XBP-1 and IRE1a IRE1a: 1 TMD Not deﬁned RT-PCR and cDNA microarray [93]





Residues 41 to 54 PCR and co-immuniprecipitation [81]
EVER1, EVER2, ZnT-1 EVER1: 10 TMDs
EVER2: 8 TMDs
ZnT-1: 6 TMDs
Not deﬁned Yeast two hybrid assay [122]
Calnexin 1 TMD 1st TMD Co-immunoprecipitation [86]
ErbB4 1 TMD Not deﬁned Co-immunoprecipitation western blot
analysis, RT-PCR, mammalian two
hybrid experiment
[78]
Calpactin I – 20 aa at C-terminus,
TMD3
[89]
Bap31 3 TMDs Last 10 aa of 3rd TMD Yeast two hybrid assay [91]
MHC I, HLA-I
(00826)
1 TMD With leucine pairs in
1st TMD








1 TMD SVM model [96]
Integral Membrane proteins
(08387, 15517, 09463)
8 (08387) and 9 TMDs SVM model [96]
Cell adhesion proteins
(06953, 07562, 09392, 06955, 06956)
1 TMD SVM model [96]
Receptor kinase
(02790, 01554, 01266, 02997, 01555)
1 TMD SVM model [96]
G-protein coupled receptors
(00045, 01347, 11809, 00678, 03614, 03576, 01628)
7 TMDs SVM model [96]
Cell surface receptors
(04713)





1 TMD SVM model [96]
Preadipocyte factor 1
(01446)
1 TMD SVM model [96]
Delta like protein
(05957)
1 TMD SVM model [96]
Notch 4
(01290)
1 TMD SVM model [96]
Notch 2
(02606)
1 TMD SVM model [96]
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state NMR spectroscopic data give evidence that both helices align
parallel to the surface of the lipid membrane [36,37], solution NMR
study also suggests a more globular alignment of these helices [34].
2.2. Interaction with TASK
Evidence that Vpu interacts not only with itself and CD4 derives
from an investigation inwhich it has been shown that Vpu also interactswith the TWIK-related acid-sensitive K+ channel (TASK) and blocks its
activity [38] (TWIK stands for tandem pore weakly inward rectifying K
channel). Sequence similarity with the ﬁrst TMD of TASK suggests that
Vpu replaces the TASK–TMD and with this impairs the function of
TASK. It is found that the consequence of the interaction is a depolariza-
tion of themembrane potential [39]. Since it could be shown that mem-
brane depolarization per se enhances viral release, it is proposed that the
effect of Vpu is, to stimulate budding bymediating depolarization of the
plasma membrane. In a more recent study based on cell growth assays
1117W.B. Fischer et al. / Biochimica et Biophysica Acta 1838 (2014) 1113–1121with yeast and a K+-uptake deﬁcient strain the depolarization effect by
modulation of the K-ion concentration is attributed to Vpu to form
channels [40].
2.3. Interaction with BST-2
Another membrane protein with which Vpu interacts via its TMDs is
the interferon induced CD317/tetherin/BST-2 [41–45] (Table 1). BST-2 di-
merizes and is incorporated into lipid rafts [46]. BST-2 is known to inhibit
viral release by tethering virions to the infected cell surface [41,42]. Vpu
recruits theβ-TrCPubiquitin ligase complexwhich leads to ubiquitination
and consequent down-regulation of BST-2. The simultaneous phosphory-
lation of both serines, Ser-52 and Ser-56 of Vpu, are essential for this
mechanism [47]. Important to note is that for the interaction of Vpu
with BST-2 the TMDs of both proteins have been found to be relevant
(Fig. 1A). It has been shown that with a special Vpu mutant in which
the only serine (Ser-23) within the TMD is replaced by a leucine or
alanine the down-regulation is not being affected [18,48]. These experi-
ments indicate that the down-regulation is independent of ion channel
functionality since this mutation impairs channel activity [16]. Within
the TMD of Vpu alanine residues (Ala-18 and -14) are sensitive to
the mode of action [18,48] which has sparked the development of a
pharmacophoremodel [49]. First NMR spectroscopic data show evidence
of the binding of BST-2 TMDwith the alanine rim of Vpu [50]. In another
study the triple isoleucine motif, Ile-15, Ile-16, and Ile-17, has been pro-
posed to be an essential site for the interaction with BST-2 [51].
2.4. Interaction with NTB-A
Most recently it has been veriﬁed that Vpu is involved in down-
modulation of a membrane protein in infected cells relevant for the ac-
tivation of natural killer (NK) cells [52] (Table 1). NK cells are part of the
immune system and able to attack infected cells without being exposed
to infected cells ever before. In the case of Vpu, infected T-cells activate
the members of the signaling lymphocytic activation molecule (SLM)
receptor family. One of these members is the type I integral membrane
protein NTB-A, natural killer-T-and-B cell antigen, which acts as a co-
activating receptor for NK cells to initiate degranulation. It has been
shown that Vpu down-modulates this protein [53]. In contrast to the
down modulation of CD4 and BST-2 the phosphorylated cytoplasmic
sites (Ser-52 and Ser-56) of Vpu are not essential. The down-modula-
tion is not following the proteasomal pathway. It is therefore speculated
that in the presence of Vpu NTB-A is not reaching the cell membrane.
Important to note is that the mode of action is similar to BST-2, as
much as the TMD of NTB-A is responsible for it (Fig. 1A). Experiments
with a scrambled TMD sequence of Vpu, similar to the one used before
by others [7], down-modulation is not observed.
2.5. Interaction with CD74
The two major histocompatibility complexes (MHC) I [54] and the
MHC II invariant chain (Ii), also called CD74, and a precursor of a peptide
presenting MHC II (pMCH II) [55], are reported to be down-regulated by
the involvement of Vpu.MHCproteins, class I proteins, are essential to re-
port the host-own character of the cell and are also essential for present-
ing peptide antigens to initiate CD8+ T cells for defense [56]. Interaction
of the cytoplasmic domain of Vpuwith bothMHC proteins is proposed to
be necessary.
2.6. Interaction with TPR
A member of the tetratricopeptide repeat (TPR) protein family has
also been reported to interact with Vpu [57]. The 41 kDa protein con-
tains four copies of a 34-amino acid TPR motif which interacts with
Vpu. The protein is named as Vpu-binding protein (UBP). Its role is tointerfere with the interaction of UBP with HIV-1 Gag protein. A site of
Vpu-UBP interaction has not yet been identiﬁed.
2.7. Motifs for protein–protein interaction in Vpu
In a bioinformatics approach short eukaryotic linear motifs (ELMs) rel-
evant for protein–protein interactions between host proteins are proposed
to be present in HIV-1 proteins [58]. Among the few ELMs suggested for
Vpu, one motif, TRG_LysEnd_APsACLL_1 (pattern: [DERQ]…L[LVI], http://
elm.eu.org/), is a common motif in type I integral membrane proteins and
found in their membrane–water interfacial regions. It seems to be evident,
that Vpu harbors motifs common for protein–protein interaction and thus,
a considerable role of Vpu's should comprise indeed the steering of the host
cell via this type of interaction (Fig. 2).
At this stage of research themode of action, as to interactwithmem-
brane proteins of the host to steer cellular function and with it the sur-
vival of the virus, is well established. In as much ion channel function is
essential for the role of viral release enhancement is still under debate.
3. E5 of human papillomavirus 16
Human papilloma virus (HPV) plays an important role in the patho-
genesis of warts, and cancers of the skin, cervical [59] and anogenital
tract [60,61]. In the case of cervical carcinoma subtype HPV-16 belongs
to the ‘high risk’ subgroup which is highly associated with the develop-
ment of cervical cancer induced by infection with the virus. The genome
of HPV-16 encodes a number of proteins which are expressed in the
early stage of viral infection and found to be oncogenic, E6, E7 [62,63]
and E5 [64,65]. In contrast to E6 and E7, expression of E5 is often
suppressed later when the genome of HPV-16 is integrated into the
host cell genome during progression to malignant disease [66,67]. There-
fore E5 is considered to be essential in the early stage of infection [68].
There is increasing evidence that the three proteins have synergistic ef-
fects for some mechanisms within the viral infectivity cycle [69]
E5 is an 83 amino acid polytopic membrane protein harboring three
TMDs and located at the Golgi apparatus, endoplasmic reticulum and
nuclearmembrane (Fig. 1B, left). A shorter 44 amino acid bitopic E5 pro-
tein of bovine papilloma virus (BPV)with its TMD at the N terminal side
shares 27% sequence homology with this protein as well as a leucine
rich motif at both of their N termini [70,71]. Analysis of the sequence
of HPV-16 E5 sequence using the Kyte–Doolittle scale of hydrophobicity
identiﬁes the three putative TMDs [72]. E5 dimerizes on the bases of hy-
drophobic interactions of its TMDs [73], possibly in a concentration de-
pendent manner [74]. Deletion studies could not single out one TMD
responsible for dimerization [73]. Dimerization is not driven by the cys-
teines present at the N terminal side and near the C terminus since re-
ducing agents do not affect the capability of E5 to form dimers [72].
Experiments with epitope tagged E5 at both of its ends reveal that its
N-terminal side is located toward the ERwhile its C-terminus is exposed
to the cytoplasm [74]. FTIR spectroscopic investigations of short peptide
constructs, which include the putative TMDs, suggest TMDs to be helical
[75]. The peptides have been derived from solid phase peptide synthesis
(SPPS) and dissolved in buffer/triﬂuoroethanol (TFE) mixture (90 μl/
10 μl). In a similar way, CD-spectroscopic analysis has been done with
peptide constructs including the putative TMDs derived from SPPS
dissolved in variousmixtures of buffer/TFE [76]. Besides spectra record-
ings in different solvent mixtures, also a series of mixtures of the indi-
vidual peptides have been measured. The data suggest a large β-sheet
content for the ﬁrst and third TMDs and irregular structure for the
second TMD. Due to the large content of leucines in the ﬁrst and third
TMDs the authors relate the structural motif to leucine-rich repeat
(LRR) proteins which typically adopt a large content of β-fold. Second-
ary structure prediction programs for both, helical andβ-sheet structure
propose a helical motif for the three TMDs (Mahato and Fischer
unpublished results). Despite the application of almost membrane like
conditions using TFE [76] it is necessary to include more thorough
Fig. 2.Putative reaction schemesof themonomeric channel formingproteins (blue, surfacemode ofMOE suitewith highlighted backbone) into homo- or heterooligomerswithmembrane
proteins of the host (orange). It is assumed that there is equilibrium between themonomer and a homooligomeric- or bundle-like form (I). The bundle can consequently interact with the
transmembrane domains (TMDs) with the host (II). Another pathway is suggested to allow the monomer to interact with the host protein ﬁrst (III). In a consequent step the monomer-
host assembly either integrats together with other viral monomers into a viral bundle (IV) or forms an oligomeric monomer-host assembly (V).
1118 W.B. Fischer et al. / Biochimica et Biophysica Acta 1838 (2014) 1113–1121lipid-membrane like conditions in future experiments to unravel the
discrepancy in the experimental results reported above.
Recently, it has been proposed that E5 exhibits channel activity using
ﬂuorescent dye release assays with liposomes [11]. Channel activity has
been shown to be sensitive to pH, which could possibly be related to the
histidines present in TMD3. The pore size is proposed to be in a range of
1.2 to 2.8 nm using ﬂuorescein isothiocyanate conjugated dextrans of var-
ious molecular masses in the liposome assay. Based on SDS PAGE analysis
the oligomeric state of HPV-16 E5 is suggested to be hexameric and
modeled accordingly with a monomeric unit consisting of three TMDs
(Fig. 1B, right). It could be shown that rimantadine and a series of novel
compounds (named MV003 and MV006) block channel activity.
Similar to Vpu, E5 exerts multiple functions ([77,78] see for review
[71,79]).
The following host proteins are identiﬁed to be involved in protein–
protein interaction with E5 (Table 1).
3.1. Interaction with 16 kDa protein
Similar to E5 of BPV, HPV-16 E5 interacts with the 16-kDa pore-
forming protein component of the vacuolar H+-ATPase [70,80].Mutant studies with E5 of BPV show that glutamine residue at po-
sition 17 is essential for the interaction [80]. In the case of HPV-
16 E5 it seems that the hydrophobicity of TMD2 is important for
the interaction [81] as well as TMD3 [82]. With a series of E5 mu-
tants (Y63F/Y68F, H75N, H77Q, H75F/H78Q) it could be shown
that the tyrosines and histidines are comprising a binding motif
of E5 with 16 kDa protein.3.2. Interaction with HLA-I
Down-regulation of the human leukocyte antigens (HLA) class I is
observed in HPV-16 E5 expressing cell lines [83], which parallels the
same activity of E5 BPV [84]. It is proposed that the ﬁrst hydrophobic
domain of E5 is interacting with the heavy chain of HLA-I [85]. In
another study it is shown that HPV-16 E5 and HLA-I co-precipitates
together with calnexin and identiﬁes the ﬁrst TMD of E5 to be in-
volved in the association [86]. Mutating three leucine residues to
proline, aspartate and arginine (triple mutant L18P/L23D/L28R)
within TMD1 abrogates interaction with calnexin and down-
regulation of HLA-I.
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ﬁrst and the last two TMDs, respectively, a simultaneous binding of a
single E5 protein with both proteins is proposed [85].
3.3. Interaction with growth factors EGFR and ErB4
E5 protein of HPV-6 associates with the epidermal growth factor
receptor (EGFR), platelet-derived growth factor (PDGF) and ErbB2, but
HPV-16 E5 does not [87]. However, in the presence of HPV-16 E5
recycling of EGFR to the cell surface is increased [88]. The C terminal
part of E5 including the last 5 amino acids is important for binding
and initiating over-activation of EGFR [82].
E5 interacts with ErbB4 amember of the tyrosine kinase growth fac-
tor family ErbB [78]. The TMD of ErbB4 and extracellular domains of
ErbB4 are necessary for binding. This implies that possibly the TMDs
of E5 are involved in the binding.
3.4. Promoting perinuclear fusion of membrane koilocytosis
Membrane fusion regulating complex calpactin I is a target of E5
[69,89]. Calpactin I is a heterodimer of two annexin A2 and p11 sub-
units. Binding via its 20 C-terminal amino acids to both subunits of
calpactin I, E5 promotes perinuclear redistribution of calpactin I with
the consequence of formation of koilocytotic vacuoles by perinuclear
membrane fusion. The 20 amino acids of E5 fully include its TMD3.
Deletion of only 10 C-terminal amino acids leaves the protein with
half of its activity [69].
3.5. ER transport protein, gap junctions and others
For regulating Bap31, a polytopic B-cell receptor-associated (Bap)
membrane protein involved in the export of transmembrane proteins
from the ER [90], the last 10 amino acids of the C-terminus of E5 are
found to be essential [91]. Similarly, the last 10 amino acids of E5 are
also relevant to associate with karyopherin β3, a member of the nuclear
import receptor family [92]. Interference with the stress response of
cells in the presence of E5 indicates that especially residues in TMD3
are highly relevant such as His-77 and Tyr-63 [93].
Furthermore, E5 is also involved in down-regulation of connexin 43
[94] and alteration of lipid composition in infected cells [95].
It has also been predicted that E5 interacts with a series of host fac-
tors using bioinformatics approaches based on support vector machine
(SVM) models [96] (Table 1).
4. p7 of hepatitis C virus
The p7 HCV is expressed as part of a large polyprotein which is
cleaved by cellular and viral proteases into ten cleavage products
([97,98], for a recent review see [99]). It is a 63 residue, 6-7 kDa
polytopic membrane protein with two TMDs linked via a very short
loop (Fig. 1C). Its role is expected to be active during entry into the
host cell [100]. Furthermore it is also essential for particle assembly
[101,102]. The two TMDs are connected via a short hydrophilic seg-
ment; both ends of the TMDs are found to point into the ER lumen
[103]. Channel characteristics identify p7 to be a weak cation selective
channel [104–106] which is sensitive to the presence of Cu2+ [107]
and small ligands [108].
The oligomerization state of p7 is dependent on the protein:deter-
gent ratio (C12E8) when using sedimentation experiments [105]. At
lower ratio a hexameric assembly is proposedwhich can shift to slightly
higher numbers at higher ratios. These ﬁndings are supported by cryo
EMpictures of assembled p7 proteins in either hexameric or heptameric
form [109–111]. Structural information is currently still on the bases of
NMR spectroscopic investigations suggesting that the overall two TMDs
can each be subdivided into two small helical sections [105,112,113].Computational models have been generated supporting the role of
histidines as pore lining residues [114,115].
Interactions of p7with host factors are proposed using the same bio-
informatics approaches as mentioned above [96], as well as a genetic
screening approach [116] (Table 1). Some of the host proteins are iden-
tiﬁed as globular proteins [116]. The proposed membrane proteins are
as follows [96]:
- Netrin-G1 ligand (protein binding), which stimulates the growth of
embryonic thalamic axons by binding of netrin-G1 [117] (single TMD)
- Preadipocyte factor 1 (growth factor), involved in cell differentiation
of adipocytes (reviewed in [118] (single TMD)
- Notches 4 and 2 (cell surface receptors) involved in cell signaling
[119] (single TMD).
Experimental evidence of interactions has not yet been reported but
is proposed to play a major role in future drug therapy [120].
5. Conclusion
The lipid membrane is a unique location for proteins. Similar to the
cytoplasm of the cell, it seems to be used for protein–protein communi-
cation. The hydrophobic nature of the membrane restrains the applica-
tion of amino acids being used. Yet, a complicated communication
network in respect of speciﬁcity of interactions is established. The pro-
teins presented in this review are found to homo-oligomerize and to
form dimers and possibly also hetero-oligomers with host factors
(Fig. 2). It is fascinating to learn about the directionality of the interac-
tions between these proteins and speciﬁcally the interaction between
their TMDs. The consequences will be highly important when it comes
to manufacture complex membrane proteins or to develop novel con-
cepts in antiviral therapy.
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